Research
Metabolic adaptation
Tirzepatide significantly reduces body mass index, waist circumference, blood pressure, and atherosclerotic cardiovascular disease risk.
Tirzepatide may improve overall cardiometabolic health in non-diabetic obese patients.
StrongSupportsmedium confidence
Meta-analyses confirmed higher odds of ≥5–20% weight loss versus semaglutide and liraglutide, significantly reducing body mass index, waist circumference, blood pressure, and atherosclerotic cardiovascular disease risk.
Why this rating
Supported by meta-analyses of clinical trials.
Source
Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
Mohammed Sallam et al. · Obesities · 2025
DOI 10.3390/obesities5020026
Meta-analysisCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →